SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001395064-22-000060
Filing Date
2022-04-21
Accepted
2022-04-21 06:06:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 SC 13D sc13d_042122.htm SC 13D 105526
2 EX-1 exhibit1_042122.htm EX-1 1983
3 EX-2 exhibit2_042122.htm EX-2 6929
  Complete submission text file 0001395064-22-000060.txt   115958
Mailing Address 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Business Address 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668 81332782111
TAKEDA PHARMACEUTICAL CO LTD (Filed by) CIK: 0001395064 (see all company filings)

IRS No.: 000000000
Type: SC 13D
SIC: 2834 Pharmaceutical Preparations

Mailing Address 343 OYSTER POINT BLVD #200 SOUTH SAN FRANCISCO CA 94080
Business Address 343 OYSTER POINT BLVD #200 SOUTH SAN FRANCISCO CA 94080 650-870-1000
Calithera Biosciences, Inc. (Subject) CIK: 0001496671 (see all company filings)

IRS No.: 272366329 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88349 | Film No.: 22839593
SIC: 2834 Pharmaceutical Preparations